CCL2 and Fabry disease: Specifically, we demonstrated that plasmatic levels of TNF-α, VEGFA, and MCP-1 are significantly increased in FD patients and that TNF-α, MCP-1, and ADAMTS-13 concentrations showed a significant decrease over time in ERT-treated patients.